NanoViricides, Inc. (NYSE American: NNVC) will present at the PODD 2025 Conference on Monday, October 27, at 3 p.m. ET in Track 5A at the Westin Copley Hotel in Boston. President and Executive Chairman Anil R. Diwan, PhD, will provide updates on the company's antiviral drug pipeline and platform technologies available for licensing. This presentation comes as the company advances its lead candidate, NV-387, toward Phase II clinical trials for MPox and respiratory viral infections.
The company's nanoviricide technology platform represents a novel approach to antiviral therapy, creating special purpose nanomaterials designed to prevent viral escape. Preclinical studies have demonstrated strong efficacy for NV-387 against respiratory syncytial virus (RSV), Influenza A, and various coronaviruses. This broad-spectrum capability positions NV-387 as a potential multi-indication therapeutic that could address multiple respiratory viral threats with a single drug candidate.
NanoViricides operates through a unique business model based on licensing technology from TheraCour Pharma Inc. for specific antiviral applications. The company holds exclusive, sub-licensable field licenses for drugs developed in several licensed fields from TheraCour. According to information available at https://www.nanoviricides.com, the company maintains worldwide exclusive perpetual licenses for this technology targeting numerous human viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Influenza, Dengue viruses, and certain coronaviruses.
The potential impact of NanoViricides' platform technology extends across multiple therapeutic areas. Beyond NV-387 for respiratory infections and MPox, the company is developing NV-HHV-1 for shingles treatment and has programs targeting oral and genital herpes, viral eye diseases including EKC and herpes keratitis, and other significant viral threats. The company's approach to creating broad-spectrum antivirals could revolutionize treatment paradigms by providing single therapeutic options for multiple viral infections.
For the pharmaceutical industry, NanoViricides' presentation at PODD 2025 represents an opportunity to showcase innovative antiviral approaches at a time when global health systems remain concerned about pandemic preparedness. The company's technology platform, based on the TheraCour nanomedicine technology licensed from AllExcel, offers potential solutions to address the constant evolution of viral threats and the limitations of current antiviral treatments. Additional details about the company's technology and programs can be found at https://ibn.fm/NNVC.
The advancement of NV-387 toward Phase II trials signals progress in addressing significant unmet medical needs in respiratory viral infections. With demonstrated preclinical efficacy against multiple virus types, this candidate could potentially reduce the burden on healthcare systems by providing a single therapeutic option for multiple respiratory pathogens. The company's broad pipeline targeting various viral diseases positions it as a significant player in the antiviral drug development landscape, though as with all pharmaceutical development, success depends on demonstrating sufficient effectiveness and safety in human clinical trials.
